[HTML][HTML] SELECT: a phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor–mutant non–small-cell lung cancer

NA Pennell, JW Neal, JE Chaft, CG Azzoli… - Journal of Clinical …, 2019 - ncbi.nlm.nih.gov
Purpose Given the pivotal role of epidermal growth factor receptor (EGFR) inhibitors in
advanced EGFR-mutant non–small-cell lung cancer (NSCLC), we tested adjuvant erlotinib …

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

NA Pennell, JW Neal, JE Chaft, CG Azzoli… - Journal of Clinical …, 2018 - europepmc.org
PURPOSE Given the pivotal role of epidermal growth factor receptor (EGFR) inhibitors in
advanced EGFR-mutant non-small-cell lung cancer (NSCLC), we tested adjuvant erlotinib in …

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer

NA Pennell, JW Neal, JE Chaft… - Journal of clinical …, 2019 - pubmed.ncbi.nlm.nih.gov
Purpose Given the pivotal role of epidermal growth factor receptor (EGFR) inhibitors in
advanced EGFR-mutant non-small-cell lung cancer (NSCLC), we tested adjuvant erlotinib in …

[HTML][HTML] SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer

NA Pennell, JW Neal, JE Chaft, CG Azzoli… - Journal of clinical …, 2019 - ncbi.nlm.nih.gov
PURPOSE Given the pivotal role of epidermal growth factor receptor (EGFR) inhibitors in
advanced EGFR-mutant non-small-cell lung cancer (NSCLC), we tested adjuvant erlotinib in …

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer

NA Pennell, JW Neal, JE Chaft, CG Azzoli… - Journal of Clinical …, 2019 - ascopubs.org
Purpose Given the pivotal role of epidermal growth factor receptor (EGFR) inhibitors in
advanced EGFR-mutant non–small-cell lung cancer (NSCLC), we tested adjuvant erlotinib …

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer

NA Pennell, JW Neal, JE Chaft, CG Azzoli… - Journal of Clinical …, 2019 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Purpose</jats: title>< jats: p> Given the pivotal role of epidermal
growth factor receptor (EGFR) inhibitors in advanced EGFR-mutant non–small-cell lung …

Select: A phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small-cell lung cancer

NA Pennell, JW Neal, JE Chaft, CG Azzoli… - Journal of Clinical …, 2019 - profiles.wustl.edu
PURPOSE: Given the pivotal role of epidermal growth factor receptor (EGFR) inhibitors in
advanced EGFR-mutant non-small-cell lung cancer (NSCLC), we tested adjuvant erlotinib in …

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

NA Pennell, JW Neal, JE Chaft, CG Azzoli… - Journal of Clinical …, 2018 - europepmc.org
Purpose Given the pivotal role of epidermal growth factor receptor (EGFR) inhibitors in
advanced EGFR-mutant non-small-cell lung cancer (NSCLC), we tested adjuvant erlotinib in …